New drugs are currently approved through clinical trials that typically cost billions of dollars and take many years to complete. As , evidence keeps adding up that AI is a potential alternative. Now another study that the AI method of drug discovery is up to 250 times more efficient than the traditional method.The AI method has the potential to:
A $50 Billion AI Drug Discovery Revolution Is Underway
The following 8 clinical-stage small cap companies are using AI to facilitate their discovery and development of new drugs and trade on various Canadian and American stock exchanges and are constituents in munKNEE’s new AI-focused Drug Discovery Stocks Index. They are listed in order of their stock performances last week along with their YTD performances, market capitalizations, a description of each, and links to the most recent news on each where present.The munKNEE AI-focused Drug Discovery Stocks Index
- Company Description:
- RXRX specializes in drug discovery through machine learning using its proprietary Recursion Operating System and has one of the world’s most extensive biological and chemical datasets.
- It has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Recursion claims to conduct millions of experiments per week using supercomputers, machine learning and automated robotic labs.
- Market Capitalization: $2.1B
- New: Recursion Pharmaceuticals: Small Company, Big Future
- Company Description:
- is focused on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Market Capitalization: $254M
- News: Absci Corp (ABSI) Stock: What the Analysts are Saying
- Company Description:
- LTRN specializes in developing new classes of precision cancer drugs with novel mechanisms of action and “recycling” previously unsuccessful cancer drugs using machine learning algorithms, genomic data, and novel precision oncology biomarkers.
- Market Capitalization: $46M
- Report: Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
- Company Description:
- ABCL develops antibody therapeutics using AI focusing on searching and analyzing the immune systems to find potential antibodies, then outsourcing their initial findings to their partners for further drug discovery.
- Market Capitalization: $1.6B
- Report: AbCellera Reports Q3 2023 Business Results
- Company Description:
- SDGR offers specialized solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Market Capitalization: $2.3B
- News: Buy Rating on Schrodinger’s Stock: Promising Clinical Data and Pipeline Expansion
- Company Description:
- RLAY specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detects and characterizes interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Market Capitalization: $1.2B
- Report: Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Company Description:
- EXAI reported the first AI-designed drug candidate to enter clinical trials and has expanded its AI-based platform to develop novel therapeutic antibodies through generative AI design.
- Exscientia is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Market Capitalization: $733M
- News: Wall Street Analysts Think Exscientia Could Surge 68.03%: Read This Before Placing a Bet
- Company Description:
- BTAI leverages existing approved drugs and/or clinically evaluated product candidates together with big data and machine learning algorithms to identify new therapeutic applications.
- Most of their drug candidates fit within the field of neuroscience disorders but the company’s pipeline also includes clinical studies for combining small molecule cancer drugs with an antibody pembrolizumab, for specific cancer cases.
- Market Capitalization: $93M
- News: Strong Buy for BioXcel: Expanding Neurology Pipeline & Promising Opioid Withdrawal Treatment
SummaryOn average, the above 8 stocks were up 10.6% last week but are still down 14.3% YTD.More By This Author:
